Table 1.

Information reported in published phase II clinical trials.

Essential metabolic comorbidities and daily lifestyle
Author	Drug	T2DM	HOMA	AHT	Dyslipidaemia	BMI	Metabolic syndrome	Alcohol	Dietary habits	Smoking	Exercise
Neuschwander-Tetri, 2014	Obeticholic acid	Yes	Yes	Yes	Yes	Yes	No	No	No	No	No
Friedman, 2018	Cenicriviroc	Yes	No	No	Yes	Yes	Yes	No	No	No	No
Ratziu, 2016	Elafibranor	Yes	Yes	Yes	Yes	Yes	No	No	No	No	No
Armstrong, 2016	Liraglutide	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No
Loomba, 2018	Selonsertib	Yes	No	No	No	Yes	No	No	No	No	No
Sanyal, 2018	Pegbelfermin	Yes	No	No	Yes	Yes	No	No	No	No	No
Harrison, 2018	NGM282	Yes	No	Yes	Yes	Yes	No	No	No	No	No
Traussnigg, 2019	norUDCA	Yes	No	Yes	No	Yes	No	No	No	No	No
Loomba, 2018	GS-0976	Yes	Yes	No	No	Yes	No	No	No	No	No
Harrison, 2020	Emricasan	Yes	No	No	Yes	Yes	Yes	No	No	No	No

Concomitant drugs
Author	Drug	T2DM therapy (%)	T2DM therapy (individualised)	AHT therapy (%)	AHT therapy (individualised)	Dyslipidaemia therapy (%)	Dyslipidaemia therapy (individualised)
Neuschwander-Tetri, 2014	Obeticholic acid	Yes	Yes	No	No	Yes	No
Friedman, 2018	Cenicriviroc	No	No	No	No	No	No
Ratziu, 2016	Elafibranor	Yes	Yes	No	No	Yes	Yes
Armstrong, 2016	Liraglutide	Yes	Yes	Yes	No	Yes	No
Loomba, 2018	Selonsertib	No	No	No	No	No	No
Sanyal, 2018	Pegbelfermin	No	No	No	No	Yes	Yes
Harrison, 2018	NGM282	Yes	Yes	Yes	No	Yes	Yes
Traussnigg, 2019	norUDCA	No	No	No	No	No	No
Loomba, 2018	GS-0976	No	No	No	No	No	No
Harrison, 2020	Emricasan	No	No	No	No	No	No

This information has been obtained from the manuscripts and corresponding supplementary material.